nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—SLC6A3—attention deficit hyperactivity disorder	0.315	0.401	CbGaD
Amphetamine—SLC6A4—attention deficit hyperactivity disorder	0.235	0.3	CbGaD
Amphetamine—DRD2—attention deficit hyperactivity disorder	0.234	0.299	CbGaD
Amphetamine—SLC6A2—locus ceruleus—attention deficit hyperactivity disorder	0.00884	0.129	CbGeAlD
Amphetamine—CARTPT—forebrain—attention deficit hyperactivity disorder	0.00528	0.0769	CbGeAlD
Amphetamine—SLC6A2—autonomic nervous system—attention deficit hyperactivity disorder	0.0047	0.0684	CbGeAlD
Amphetamine—CARTPT—nervous system—attention deficit hyperactivity disorder	0.00287	0.0417	CbGeAlD
Amphetamine—TAAR1—nervous system—attention deficit hyperactivity disorder	0.00287	0.0417	CbGeAlD
Amphetamine—CARTPT—central nervous system—attention deficit hyperactivity disorder	0.00276	0.0402	CbGeAlD
Amphetamine—TAAR1—central nervous system—attention deficit hyperactivity disorder	0.00276	0.0402	CbGeAlD
Amphetamine—CARTPT—cerebellum—attention deficit hyperactivity disorder	0.0027	0.0393	CbGeAlD
Amphetamine—CARTPT—brain—attention deficit hyperactivity disorder	0.00219	0.0319	CbGeAlD
Amphetamine—SLC18A2—forebrain—attention deficit hyperactivity disorder	0.00179	0.0261	CbGeAlD
Amphetamine—SLC6A3—forebrain—attention deficit hyperactivity disorder	0.00136	0.0198	CbGeAlD
Amphetamine—SLC6A4—forebrain—attention deficit hyperactivity disorder	0.00124	0.0181	CbGeAlD
Amphetamine—SLC18A2—midbrain—attention deficit hyperactivity disorder	0.00119	0.0172	CbGeAlD
Amphetamine—MAOB—forebrain—attention deficit hyperactivity disorder	0.00118	0.0172	CbGeAlD
Amphetamine—SLC6A2—forebrain—attention deficit hyperactivity disorder	0.0011	0.0159	CbGeAlD
Amphetamine—MAOB—cardiovascular system—attention deficit hyperactivity disorder	0.001	0.0146	CbGeAlD
Amphetamine—DRD2—forebrain—attention deficit hyperactivity disorder	0.000998	0.0145	CbGeAlD
Amphetamine—SLC18A2—nervous system—attention deficit hyperactivity disorder	0.000974	0.0142	CbGeAlD
Amphetamine—SLC18A2—central nervous system—attention deficit hyperactivity disorder	0.000938	0.0137	CbGeAlD
Amphetamine—SLC18A2—cerebellum—attention deficit hyperactivity disorder	0.000917	0.0133	CbGeAlD
Amphetamine—SLC6A3—midbrain—attention deficit hyperactivity disorder	0.000896	0.013	CbGeAlD
Amphetamine—SLC6A4—midbrain—attention deficit hyperactivity disorder	0.000821	0.012	CbGeAlD
Amphetamine—CYP2A6—cerebellum—attention deficit hyperactivity disorder	0.000819	0.0119	CbGeAlD
Amphetamine—MAOB—midbrain—attention deficit hyperactivity disorder	0.000781	0.0114	CbGeAlD
Amphetamine—SLC18A2—brain—attention deficit hyperactivity disorder	0.000745	0.0108	CbGeAlD
Amphetamine—SLC6A3—nervous system—attention deficit hyperactivity disorder	0.000737	0.0107	CbGeAlD
Amphetamine—Tolazoline—ADRA2C—attention deficit hyperactivity disorder	0.000717	0.0936	CrCbGaD
Amphetamine—SLC6A3—central nervous system—attention deficit hyperactivity disorder	0.000709	0.0103	CbGeAlD
Amphetamine—SLC22A3—nervous system—attention deficit hyperactivity disorder	0.000694	0.0101	CbGeAlD
Amphetamine—SLC6A3—cerebellum—attention deficit hyperactivity disorder	0.000693	0.0101	CbGeAlD
Amphetamine—SLC6A4—nervous system—attention deficit hyperactivity disorder	0.000675	0.00983	CbGeAlD
Amphetamine—SLC22A3—central nervous system—attention deficit hyperactivity disorder	0.000668	0.00972	CbGeAlD
Amphetamine—CYP2A6—brain—attention deficit hyperactivity disorder	0.000665	0.00968	CbGeAlD
Amphetamine—DRD2—midbrain—attention deficit hyperactivity disorder	0.000659	0.00959	CbGeAlD
Amphetamine—SLC6A4—central nervous system—attention deficit hyperactivity disorder	0.00065	0.00946	CbGeAlD
Amphetamine—MAOB—nervous system—attention deficit hyperactivity disorder	0.000642	0.00934	CbGeAlD
Amphetamine—MAOB—central nervous system—attention deficit hyperactivity disorder	0.000618	0.009	CbGeAlD
Amphetamine—SLC22A5—midbrain—attention deficit hyperactivity disorder	0.000614	0.00893	CbGeAlD
Amphetamine—MAOB—cerebellum—attention deficit hyperactivity disorder	0.000604	0.00879	CbGeAlD
Amphetamine—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.0006	0.00873	CbGeAlD
Amphetamine—SLC6A2—nervous system—attention deficit hyperactivity disorder	0.000594	0.00865	CbGeAlD
Amphetamine—SLC6A2—central nervous system—attention deficit hyperactivity disorder	0.000572	0.00833	CbGeAlD
Amphetamine—SLC6A3—brain—attention deficit hyperactivity disorder	0.000563	0.0082	CbGeAlD
Amphetamine—DRD2—nervous system—attention deficit hyperactivity disorder	0.000542	0.00788	CbGeAlD
Amphetamine—SLC22A3—brain—attention deficit hyperactivity disorder	0.00053	0.00772	CbGeAlD
Amphetamine—Pargyline—MAOA—attention deficit hyperactivity disorder	0.000522	0.0681	CrCbGaD
Amphetamine—DRD2—central nervous system—attention deficit hyperactivity disorder	0.000522	0.00759	CbGeAlD
Amphetamine—SLC6A4—brain—attention deficit hyperactivity disorder	0.000516	0.00751	CbGeAlD
Amphetamine—Diethylpropion—SLC6A3—attention deficit hyperactivity disorder	0.000513	0.0669	CrCbGaD
Amphetamine—DRD2—cerebellum—attention deficit hyperactivity disorder	0.00051	0.00742	CbGeAlD
Amphetamine—MAOB—brain—attention deficit hyperactivity disorder	0.000491	0.00714	CbGeAlD
Amphetamine—SLC22A5—cerebellum—attention deficit hyperactivity disorder	0.000475	0.00691	CbGeAlD
Amphetamine—SLC6A2—brain—attention deficit hyperactivity disorder	0.000454	0.00661	CbGeAlD
Amphetamine—DRD2—brain—attention deficit hyperactivity disorder	0.000414	0.00603	CbGeAlD
Amphetamine—Methamphetamine—ADRA2C—attention deficit hyperactivity disorder	0.000398	0.0519	CrCbGaD
Amphetamine—Lisdexamfetamine—SLC6A3—attention deficit hyperactivity disorder	0.000389	0.0507	CrCbGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000388	0.00278	CbGpPWpGaD
Amphetamine—SLC22A5—brain—attention deficit hyperactivity disorder	0.000386	0.00561	CbGeAlD
Amphetamine—DRD2—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.000374	0.00268	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000366	0.00263	CbGpPWpGaD
Amphetamine—DRD2—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.000362	0.00259	CbGpPWpGaD
Amphetamine—MAOB—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000359	0.00257	CbGpPWpGaD
Amphetamine—DRD2—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.000356	0.00255	CbGpPWpGaD
Amphetamine—DRD2—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.000351	0.00252	CbGpPWpGaD
Amphetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—attention deficit hyperactivity disorder	0.000349	0.0025	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000339	0.00243	CbGpPWpGaD
Amphetamine—Tranylcypromine—MAOA—attention deficit hyperactivity disorder	0.000337	0.0439	CrCbGaD
Amphetamine—TAAR1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000333	0.00238	CbGpPWpGaD
Amphetamine—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.000326	0.00474	CbGeAlD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—GABRQ—attention deficit hyperactivity disorder	0.00032	0.00229	CbGpPWpGaD
Amphetamine—Phenylpropanolamine—MAOA—attention deficit hyperactivity disorder	0.000317	0.0413	CrCbGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000315	0.00226	CbGpPWpGaD
Amphetamine—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.000313	0.00456	CbGeAlD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC9A9—attention deficit hyperactivity disorder	0.000307	0.0022	CbGpPWpGaD
Amphetamine—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.000306	0.00446	CbGeAlD
Amphetamine—Tolazoline—ADRA2A—attention deficit hyperactivity disorder	0.000306	0.0399	CrCbGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000305	0.00219	CbGpPWpGaD
Amphetamine—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—attention deficit hyperactivity disorder	0.000302	0.00216	CbGpPWpGaD
Amphetamine—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—attention deficit hyperactivity disorder	0.000301	0.00216	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.0003	0.00215	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000296	0.00212	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000295	0.00212	CbGpPWpGaD
Amphetamine—Phenylpropanolamine—DRD1—attention deficit hyperactivity disorder	0.000288	0.0375	CrCbGaD
Amphetamine—Phentermine—MAOA—attention deficit hyperactivity disorder	0.000282	0.0368	CrCbGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000276	0.00198	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—CACNB2—attention deficit hyperactivity disorder	0.000275	0.00197	CbGpPWpGaD
Amphetamine—Phenylpropanolamine—SLC6A3—attention deficit hyperactivity disorder	0.000273	0.0356	CrCbGaD
Amphetamine—DRD2—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.000273	0.00195	CbGpPWpGaD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC9A9—attention deficit hyperactivity disorder	0.000272	0.00195	CbGpPWpGaD
Amphetamine—Phenylpropanolamine—ADRA2A—attention deficit hyperactivity disorder	0.000268	0.0349	CrCbGaD
Amphetamine—Pseudoephedrine—MAOA—attention deficit hyperactivity disorder	0.000267	0.0349	CrCbGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—TPH2—attention deficit hyperactivity disorder	0.000262	0.00188	CbGpPWpGaD
Amphetamine—Selegiline—MAOA—attention deficit hyperactivity disorder	0.000261	0.034	CrCbGaD
Amphetamine—TAAR1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000258	0.00185	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—GRM7—attention deficit hyperactivity disorder	0.00025	0.00179	CbGpPWpGaD
Amphetamine—CYP2D6—brain—attention deficit hyperactivity disorder	0.000249	0.00362	CbGeAlD
Amphetamine—TAAR1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000246	0.00176	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—GABRQ—attention deficit hyperactivity disorder	0.000245	0.00176	CbGpPWpGaD
Amphetamine—Phentermine—SLC6A3—attention deficit hyperactivity disorder	0.000243	0.0317	CrCbGaD
Amphetamine—TAAR1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000241	0.00172	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00024	0.00172	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.000236	0.00169	CbGpPWpGaD
Amphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—attention deficit hyperactivity disorder	0.000235	0.00168	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000232	0.00167	CbGpPWpGaD
Amphetamine—Dextroamphetamine—SLC6A3—attention deficit hyperactivity disorder	0.000232	0.0303	CrCbGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.000232	0.00166	CbGpPWpGaD
Amphetamine—Pseudoephedrine—SLC6A3—attention deficit hyperactivity disorder	0.000231	0.0301	CrCbGaD
Amphetamine—Phenelzine—MAOA—attention deficit hyperactivity disorder	0.00023	0.03	CrCbGaD
Amphetamine—DRD2—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.000229	0.00164	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000228	0.00164	CbGpPWpGaD
Amphetamine—Pseudoephedrine—ADRA2A—attention deficit hyperactivity disorder	0.000226	0.0295	CrCbGaD
Amphetamine—TAAR1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000226	0.00162	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—CHRNA4—attention deficit hyperactivity disorder	0.000226	0.00162	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000223	0.0016	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000221	0.00158	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.00022	0.00157	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000219	0.00157	CbGpPWpGaD
Amphetamine—CYP2D6—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.000216	0.00155	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—TPH2—attention deficit hyperactivity disorder	0.000214	0.00153	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.00021	0.00151	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00021	0.00151	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—SNAP25—attention deficit hyperactivity disorder	0.00021	0.0015	CbGpPWpGaD
Amphetamine—Methamphetamine—MAOA—attention deficit hyperactivity disorder	0.000201	0.0262	CrCbGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.0002	0.00144	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.0002	0.00143	CbGpPWpGaD
Amphetamine—SLC6A4—NRF2 pathway—SLC6A3—attention deficit hyperactivity disorder	0.000197	0.00141	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000196	0.00141	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—SLC6A3—attention deficit hyperactivity disorder	0.000196	0.0014	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.000193	0.00138	CbGpPWpGaD
Amphetamine—MAOB—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000192	0.00138	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000191	0.00137	CbGpPWpGaD
Amphetamine—MAOB—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000191	0.00137	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000191	0.00137	CbGpPWpGaD
Amphetamine—SLC6A2—NRF2 pathway—SLC6A4—attention deficit hyperactivity disorder	0.00019	0.00136	CbGpPWpGaD
Amphetamine—Phentermine—SLC6A4—attention deficit hyperactivity disorder	0.000182	0.0237	CrCbGaD
Amphetamine—SLC18A2—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.000181	0.0013	CbGpPWpGaD
Amphetamine—CYP2A6—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000175	0.00125	CbGpPWpGaD
Amphetamine—Methamphetamine—SLC6A3—attention deficit hyperactivity disorder	0.000173	0.0226	CrCbGaD
Amphetamine—Pseudoephedrine—SLC6A4—attention deficit hyperactivity disorder	0.000172	0.0225	CrCbGaD
Amphetamine—Benzphetamine—SLC6A3—attention deficit hyperactivity disorder	0.000172	0.0224	CrCbGaD
Amphetamine—SLC6A4—Circadian rythm related genes—DRD1—attention deficit hyperactivity disorder	0.000171	0.00123	CbGpPWpGaD
Amphetamine—Methamphetamine—ADRA2A—attention deficit hyperactivity disorder	0.00017	0.0222	CrCbGaD
Amphetamine—SLC6A2—NRF2 pathway—SLC6A3—attention deficit hyperactivity disorder	0.000169	0.00121	CbGpPWpGaD
Amphetamine—Benzphetamine—ADRA2A—attention deficit hyperactivity disorder	0.000169	0.022	CrCbGaD
Amphetamine—SLC6A3—NRF2 pathway—SLC6A4—attention deficit hyperactivity disorder	0.000168	0.00121	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.000168	0.00121	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—ADRA2C—attention deficit hyperactivity disorder	0.000167	0.0012	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.000167	0.0012	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	0.000166	0.00119	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—DRD3—attention deficit hyperactivity disorder	0.000166	0.00119	CbGpPWpGaD
Amphetamine—SLC18A2—Transmission across Chemical Synapses—MAOA—attention deficit hyperactivity disorder	0.000165	0.00118	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—CACNB2—attention deficit hyperactivity disorder	0.000164	0.00117	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—DRD4—attention deficit hyperactivity disorder	0.000161	0.00115	CbGpPWpGaD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.000159	0.00114	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—MAOA—attention deficit hyperactivity disorder	0.000158	0.00113	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.000156	0.00112	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.000155	0.00111	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000153	0.0011	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.000152	0.00109	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—BDNF—attention deficit hyperactivity disorder	0.000152	0.00109	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000151	0.00109	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.000151	0.00108	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—SLC6A3—attention deficit hyperactivity disorder	0.00015	0.00107	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—DRD2—attention deficit hyperactivity disorder	0.00015	0.00107	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000149	0.00107	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000147	0.00105	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000146	0.00105	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—CHRNA4—attention deficit hyperactivity disorder	0.000141	0.00101	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—SLC6A4—attention deficit hyperactivity disorder	0.000141	0.00101	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.000138	0.00099	CbGpPWpGaD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.000137	0.000983	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.000137	0.00098	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000136	0.000972	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.000133	0.000954	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000132	0.000949	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000132	0.000945	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000132	0.000944	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000131	0.000941	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—TPH2—attention deficit hyperactivity disorder	0.000131	0.000939	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—SNAP25—attention deficit hyperactivity disorder	0.000131	0.000938	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00013	0.000935	CbGpPWpGaD
Amphetamine—Methamphetamine—SLC6A4—attention deficit hyperactivity disorder	0.00013	0.0169	CrCbGaD
Amphetamine—TAAR1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000129	0.000925	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000129	0.000925	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—HTR2A—attention deficit hyperactivity disorder	0.000129	0.000922	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—COMT—attention deficit hyperactivity disorder	0.000128	0.000914	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000127	0.000913	CbGpPWpGaD
Amphetamine—SLC18A2—Neuronal System—MAOA—attention deficit hyperactivity disorder	0.000127	0.000907	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000127	0.000907	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—CACNB2—attention deficit hyperactivity disorder	0.000125	0.000899	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—SLC6A3—attention deficit hyperactivity disorder	0.000125	0.000899	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000123	0.000882	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000119	0.000855	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000119	0.000851	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000117	0.00084	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000116	0.00083	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—HRH3—attention deficit hyperactivity disorder	0.000114	0.000815	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—CHRNA4—attention deficit hyperactivity disorder	0.000108	0.000773	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000108	0.000773	CbGpPWpGaD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.000107	0.000765	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.000106	0.000756	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—DRD1—attention deficit hyperactivity disorder	0.000105	0.00075	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—SLC6A4—attention deficit hyperactivity disorder	0.000105	0.00075	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—DRD3—attention deficit hyperactivity disorder	0.000101	0.000727	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.000101	0.000727	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—SNAP25—attention deficit hyperactivity disorder	0.0001	0.000719	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	9.94e-05	0.000712	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	9.93e-05	0.000712	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—COMT—attention deficit hyperactivity disorder	9.92e-05	0.000711	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—MAOA—attention deficit hyperactivity disorder	9.85e-05	0.000706	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—DRD4—attention deficit hyperactivity disorder	9.84e-05	0.000706	CbGpPWpGaD
Amphetamine—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	9.8e-05	0.000702	CbGpPWpGaD
Amphetamine—CYP2A6—Biological oxidations—COMT—attention deficit hyperactivity disorder	9.35e-05	0.00067	CbGpPWpGaD
Amphetamine—CYP2A6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	9.28e-05	0.000665	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	9.22e-05	0.000661	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	9.04e-05	0.000648	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	8.95e-05	0.000641	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	8.95e-05	0.000641	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	8.8e-05	0.00063	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	8.69e-05	0.000623	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	8.58e-05	0.000615	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	8.54e-05	0.000612	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	8.32e-05	0.000596	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	8.3e-05	0.000595	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	8.16e-05	0.000585	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	8.06e-05	0.000578	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	8.06e-05	0.000578	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	7.9e-05	0.000566	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ADRA2C—attention deficit hyperactivity disorder	7.85e-05	0.000563	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	7.82e-05	0.000561	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	7.76e-05	0.000556	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—COMT—attention deficit hyperactivity disorder	7.6e-05	0.000545	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	7.55e-05	0.000541	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—MAOA—attention deficit hyperactivity disorder	7.55e-05	0.000541	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	7.35e-05	0.000527	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	7.27e-05	0.000521	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	7.12e-05	0.00051	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	7.04e-05	0.000505	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	6.99e-05	0.000501	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	6.97e-05	0.0005	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	6.95e-05	0.000498	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	6.92e-05	0.000496	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	6.91e-05	0.000495	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	6.88e-05	0.000493	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	6.84e-05	0.00049	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	6.81e-05	0.000488	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ADRA2C—attention deficit hyperactivity disorder	6.64e-05	0.000476	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	6.37e-05	0.000457	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	6.02e-05	0.000431	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	5.73e-05	0.000411	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	5.61e-05	0.000402	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	5.59e-05	0.000401	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	5.56e-05	0.000399	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	5.43e-05	0.000389	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	5.42e-05	0.000388	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—TPH2—attention deficit hyperactivity disorder	5.42e-05	0.000388	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CACNB2—attention deficit hyperactivity disorder	5.42e-05	0.000388	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—DPYD—attention deficit hyperactivity disorder	5.33e-05	0.000382	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	5.33e-05	0.000382	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	5.26e-05	0.000377	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	5.26e-05	0.000377	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	5.24e-05	0.000376	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	5.21e-05	0.000373	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	5.2e-05	0.000373	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	5.17e-05	0.000371	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	5.1e-05	0.000365	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CACNA1C—attention deficit hyperactivity disorder	4.96e-05	0.000355	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CACNB2—attention deficit hyperactivity disorder	4.58e-05	0.000329	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—TPH2—attention deficit hyperactivity disorder	4.58e-05	0.000329	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	4.58e-05	0.000328	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—DPYD—attention deficit hyperactivity disorder	4.51e-05	0.000323	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	4.51e-05	0.000323	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.46e-05	0.00032	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—SNAP25—attention deficit hyperactivity disorder	4.33e-05	0.00031	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CACNA1C—attention deficit hyperactivity disorder	4.19e-05	0.0003	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ADRA2A—attention deficit hyperactivity disorder	4.12e-05	0.000295	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	3.89e-05	0.000279	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.82e-05	0.000274	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—SNAP25—attention deficit hyperactivity disorder	3.66e-05	0.000263	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	3.58e-05	0.000256	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	3.53e-05	0.000253	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ADRA2A—attention deficit hyperactivity disorder	3.49e-05	0.00025	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	3.43e-05	0.000246	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	3.4e-05	0.000244	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	3.4e-05	0.000244	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—COMT—attention deficit hyperactivity disorder	3.28e-05	0.000235	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—MAOA—attention deficit hyperactivity disorder	3.26e-05	0.000234	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	3.16e-05	0.000227	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.09e-05	0.000221	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	3.07e-05	0.00022	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.06e-05	0.000219	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.01e-05	0.000216	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	3.01e-05	0.000216	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	2.97e-05	0.000213	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	2.95e-05	0.000212	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.87e-05	0.000206	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.78e-05	0.000199	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—COMT—attention deficit hyperactivity disorder	2.78e-05	0.000199	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—MAOA—attention deficit hyperactivity disorder	2.76e-05	0.000198	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2.73e-05	0.000196	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.7e-05	0.000193	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—TPH2—attention deficit hyperactivity disorder	2.64e-05	0.000189	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.64e-05	0.000189	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—DPYD—attention deficit hyperactivity disorder	2.6e-05	0.000186	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.41e-05	0.000173	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.36e-05	0.000169	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.14e-05	0.000154	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.11e-05	0.000151	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.09e-05	0.00015	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.01e-05	0.000144	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.94e-05	0.000139	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.82e-05	0.000131	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.76e-05	0.000126	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.7e-05	0.000122	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.64e-05	0.000118	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.61e-05	0.000116	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—COMT—attention deficit hyperactivity disorder	1.6e-05	0.000115	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.59e-05	0.000114	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—MAOA—attention deficit hyperactivity disorder	1.59e-05	0.000114	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	1.48e-05	0.000106	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.48e-05	0.000106	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	1.46e-05	0.000104	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—EP300—attention deficit hyperactivity disorder	1.41e-05	0.000101	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.35e-05	9.7e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—EP300—attention deficit hyperactivity disorder	1.19e-05	8.54e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.18e-05	8.48e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.13e-05	8.07e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.04e-05	7.46e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	8.97e-06	6.43e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	8.9e-06	6.38e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—EP300—attention deficit hyperactivity disorder	6.86e-06	4.91e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.51e-06	3.95e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	3.85e-06	2.76e-05	CbGpPWpGaD
